Rockwell Medical (NASDAQ: RMTI) and Aimmune Therapeutics (NASDAQ:AIMT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Risk & Volatility

Rockwell Medical has a beta of 2.17, indicating that its share price is 117% more volatile than the S&P 500. Comparatively, Aimmune Therapeutics has a beta of -1.03, indicating that its share price is 203% less volatile than the S&P 500.

Insider & Institutional Ownership

21.4% of Rockwell Medical shares are owned by institutional investors. Comparatively, 72.9% of Aimmune Therapeutics shares are owned by institutional investors. 15.9% of Rockwell Medical shares are owned by insiders. Comparatively, 24.6% of Aimmune Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and price targets for Rockwell Medical and Aimmune Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rockwell Medical 1 0 1 1 2.67
Aimmune Therapeutics 0 0 1 0 3.00

Rockwell Medical presently has a consensus price target of $9.33, indicating a potential upside of 18.90%. Aimmune Therapeutics has a consensus price target of $40.00, indicating a potential upside of 52.50%. Given Aimmune Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Aimmune Therapeutics is more favorable than Rockwell Medical.


This table compares Rockwell Medical and Aimmune Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Rockwell Medical -39.68% -42.22% -27.15%
Aimmune Therapeutics N/A -44.53% -42.00%

Earnings and Valuation

This table compares Rockwell Medical and Aimmune Therapeutics’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Rockwell Medical $54.04 million 7.52 -$21.07 million ($0.42) -18.69
Aimmune Therapeutics N/A N/A -$106.22 million ($2.25) -11.66

Rockwell Medical has higher revenue and earnings than Aimmune Therapeutics. Rockwell Medical is trading at a lower price-to-earnings ratio than Aimmune Therapeutics, indicating that it is currently the more affordable of the two stocks.


Rockwell Medical beats Aimmune Therapeutics on 7 of the 12 factors compared between the two stocks.

Rockwell Medical Company Profile

Rockwell Medical, Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. The Company’s drug products include Triferic (ferric pyrophosphate citrate) and Calcitriol (Active Vitamin D) Injection. Triferic is an iron compound that is delivered to hemodialysis patients through dialysate, replacing the iron loss that occurs during their dialysis treatment. Calcitriol (active vitamin D) injection is indicated for treatment of secondary hyperparathyroidism in dialysis patients.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. The Company’s lead CODIT product candidate, AR101, is an investigational biologic for the treatment of patients with peanut allergy. The Company has initiated Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE), its Phase III registration trial of AR101. The Company is in the process of evaluating additional delivery forms for AR101 for the maintenance phase.

Receive News & Ratings for Rockwell Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.